Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aligos Therapeutics, Inc. - Common stock (NQ:ALGS)

5.150 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aligos Therapeutics, Inc. - Common stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Aligos Therapeutics to Announce Fourth Quarter Results March 9, 2023
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Presents Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the Liver
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics to Present Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the Liver
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Co-Founders File Complaint Against Johnson & Johnson Alleging Fraud ↗
 
Via Benzinga
News headline image
Aligos Therapeutics to Present at the SVB Securities Global Biopharma Conference
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Reprioritizes Pipeline With Focus On NASH, COVID Programs, Cuts Another 10% Of Its Workforce ↗
 
Via Benzinga
News headline image
Aligos Therapeutics Announces Strategic Reprioritization of NASH and COVID-19 Programs and Confirms Key Timelines and Extension of Cash Runway to Year-End 2024
From Aligos Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Why Calyxt Shares Are Trading Higher By Around 116%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Celyad Oncology SA (NASDAQ: CYAD) jumped 187% to $2.30 after gaining 21% on Friday. Celyad Oncology, last month, decided to discontinue the development of its remaining clinical program... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Aligos Therapeutics on Track to Complete Phase 2-Enabling Activities in 2023 for its Clinically Validated THR-ß Drug Candidate for NASH, ALG-055009
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Gainers Swvl Holdings Corp. (NASDAQ: SWVL) surged 133% to $0.3218. Swvl recently announced the commencement of a strategic review process. 
Via Benzinga
News headline image
Aligos Therapeutics Initiates Dosing with its Small Interfering RNA (siRNA) Drug Candidate, ALG-125755, in Subjects with Chronic Hepatitis B (CHB)
Single and multiple ascending doses to be evaluated in CHB subjects throughout 2023 
From Aligos Therapeutics
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2023 ↗
 
Via Benzinga
News headline image
Aligos Therapeutics Presents Nonclinical Data for its Coronavirus Therapeutic Program at the 2022 Respi DART Meeting
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Presents Clinical Data for its NASH Program and Nonclinical Data for its Chronic Hepatitis B Portfolio at AASLD’s The Liver Meeting® 2022
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Presents Clinical Data for its Capsid Assembly Modulator, ALG-000184, at AASLD’s The Liver Meeting® 2022
Reductions in hepatitis B surface antigen levels observed in a subset of subjects with chronic hepatitis B enrolled in Phase 1 study ALG-000184-201 
From Aligos Therapeutics
Via GlobeNewswire
News headline image
SVB Leerink Maintains Market Perform Rating for Aligos Therapeutics: Here's What You Need To Know ↗
SVB Leerink has decided to maintain its Market Perform rating of Aligos Therapeutics (NASDAQ:ALGS) and lower its price target from $3.00 to $2.00. Shares of Aligos Therapeutics are trading up 0.0% over... 
Via Benzinga
News headline image
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2022 Financial Results
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics to Present Nonclinical and Clinical Data for its Chronic Hepatitis B and NASH Portfolio at AASLD’s The Liver Meeting® 2022
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics to Announce Third Quarter Results November 2, 2022
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics to Present Data on pan-Coronavirus Protease Inhibitors for the Treatment of COVID-19 at Cambridge Healthtech Institute’s 20th Annual Discovery on Target Conference, to be Held October 17-20, 2022 in Boston, MA
Aligos’ pan-Coronavirus inhibitor, ALG-097558, is on track to begin first clinical studies in 1H 2023 
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Initiates Dosing In Healthy Volunteers With siRNA Drug Candidate ALG-125755
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Files Response to Janssen Biopharma Lawsuit and Lodges Counterclaims Alleging Unfair Competition and Promissory Fraud
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics's Return On Capital Employed Overview ↗
According to Benzinga Pro data, during Q2, Aligos Therapeutics (NASDAQ:ALGS) posted sales of $3.69 million. Earnings were up 44.06%, but Aligos Therapeutics still reported an overall loss of $19.92... 
Via Benzinga
News headline image
Aligos Therapeutics Earnings Preview ↗
Aligos Therapeutics (NASDAQ:ALGS) is set to give its latest quarterly earnings report on Thursday, 2022-08-04. Here's what investors need to know before the announcement. Analysts estimate that Aligos... 
Via Benzinga
News headline image
Aligos Therapeutics to Announce Second Quarter 2022 Results August 4, 2022
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Shares Fall Following Commencement Of Initial-Stage Chronic Hepatitis B Study ↗
Aligos Therapeutics, Inc. (NASDAQ: ALGS) has initiated enrollment in a 12-week dosing cohort of HBeAg-positive chronic hepatitis B (CHB) subjects in the ongoing Phase 1b study ALG-000184-201. 
Via Benzinga
News headline image
Aligos Therapeutics's Return On Capital Employed Insights ↗
According to Benzinga Pro data, during Q1, Aligos Therapeutics (NASDAQ:ALGS) posted sales of $2.57 million. Earnings were up 5.57%, but Aligos Therapeutics still reported an overall loss of $35.62... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 5, 2022 ↗
Upgrades 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.